From a fundamental aspect, there is almost nothing I can tell you about this company. Primarily because it has zero history. The company is worth just shy of $29 million, yet it only had revenue of $289,800 through the first 9 months of the year.
This is a very early stage company, one that you need to have a ton of conviction on, and need to be well aware of the risks that it may never turn out. The technology and products it offers are definitely appealing to a post COVID and more digital technology based medical field. But, there's the product, and then there's the execution. The company will need to execute.
Best strategy for these highly speculative nano caps is to only buy what you're willing to lose. If I were to buy a company like this, it would make up no more than 0.5% of my portfolio, tops. And, I'd be buying with the knowledge that there's a good chance the company never comes to fruition.
All in all, it's got the makings of a successful company in terms of its product line. Will be interesting to see if they can produce. In terms of whether or not it's worth the hold, that's completely up to you. It's almost impossible to analyze underlying fundamentals with a very early stage company like this, so I can't provide any opinion on that front.